Reduced intestinal‐to‐diffuse conversion and immunosuppressive responses underlie superiority of neoadjuvant immunochemotherapy in gastric adenocarcinoma.

MLA

Wang, Lei, et al. “Reduced Intestinal‐to‐diffuse Conversion and Immunosuppressive Responses Underlie Superiority of Neoadjuvant Immunochemotherapy in Gastric Adenocarcinoma.” MedComm, vol. 5, no. 11, Nov. 2024, pp. 1–20. EBSCOhost, https://doi.org/10.1002/mco2.762.

APA

Wang, L., Wan, L., Chen, X., Gao, P., Hou, Y., Wu, L., Liu, W., Tian, S., Han, M., Peng, S., Tan, Y., Pan, Y., Ren, Y., Li, J., Wen, H., Liu, Q., Zhang, M., Wang, T., Qin, Z., & Xiang, J. (2024). Reduced intestinal‐to‐diffuse conversion and immunosuppressive responses underlie superiority of neoadjuvant immunochemotherapy in gastric adenocarcinoma. MedComm, 5(11), 1–20. https://doi.org/10.1002/mco2.762

Chicago

Wang, Lei, Linghong Wan, Xu Chen, Peng Gao, Yongying Hou, Linyu Wu, Wenkang Liu, et al. 2024. “Reduced Intestinal‐to‐diffuse Conversion and Immunosuppressive Responses Underlie Superiority of Neoadjuvant Immunochemotherapy in Gastric Adenocarcinoma.” MedComm 5 (11): 1–20. doi:10.1002/mco2.762.